Generic Challenge:. Martin a. Voet

Читать онлайн.
Название Generic Challenge:
Автор произведения Martin a. Voet
Жанр Медицина
Серия
Издательство Медицина
Год выпуска 0
isbn 9781627346252



Скачать книгу

Exclusivity

       Regulatory Exclusivity

       Orphan Drug Exclusivity

       New Chemical Entity (NCE) Exclusivity

       New Use/Condition of Use/Formulation Exclusivity

       Pediatric Exclusivity

       Qualified Infectious Disease Products (QIDP)

       Other Forms of Exclusivity

       Litigation Exclusivity

       Exclusivity outside the U.S.

       European Union

       Japan

       China, Australia, New Zealand and Canada

       India

       Take Home Message

Chapter 6 Generic Drugs: Hatch Waxman Act

       Historical Background

       The Law Today

       FDA Orange Book

       Patents Listed in the Orange Book

       Patent Certifications

       Suits Following Patent Certification

       Therapeutic Equivalence Rating

       Patent Use Codes

       Litigation on Scope of Patent Use Codes

       180-day Generic Product Exclusivity

       Authorized Generics

       Medicare Act Amendments

       Declaratory Judgment Actions

       Counterclaim to De-list from the Orange Book

       Agreements between Innovators and Generics

       Settlement Agreements in Europe

       Orphan Exclusivity to Block Generic Approval?

       ANDA Backlog

       Patent Challenges on the Increase

       Inter Partes Review in Hatch Waxman Cases

       Canada

       In General

       Paragraph IV Type Letters

       Listing Requirements

       NAFTA Challenge

       Exclusivity

       PMPRB

       Take Home Message

Chapter 7 Generics for Biologic Drugs

       Introduction

       The Purple Book

       Story of Erythropoietin (EPO)

       Early Approvals of Biologic Generics

       BPCIA

       Biosimilars and Interchangeables

       Exclusivity for Branded Biologics (BLAs)

       Patent Dispute Procedures for Biosimilars

       Biosimilar Litigation under BPCIA

       FDA Guidance on Biosimilar Development

       European Regulation of Biosimilars

       Biosimilars in India and Canada

       Take Home Message

Chapter 8 Putting it All Together: Product Life-Cycle Management

       In General

       FTC View: “Product Hopping”

       Patents

       Development Stage